Your browser is no longer supported. Please, upgrade your browser.
Intra-Cellular Therapies, Inc.
Index- P/E- EPS (ttm)-3.16 Insider Own2.00% Shs Outstand80.95M Perf Week3.14%
Market Cap3.03B Forward P/E- EPS next Y-1.82 Insider Trans-16.69% Shs Float77.20M Perf Month18.83%
Income-232.30M PEG- EPS next Q-0.82 Inst Own87.80% Short Float8.85% Perf Quarter-4.82%
Sales37.60M P/S80.67 EPS this Y-20.50% Inst Trans4.46% Short Ratio12.45 Perf Half Y44.70%
Book/sh7.56 P/B4.91 EPS next Y44.10% ROA-35.70% Target Price51.63 Perf Year67.95%
Cash/sh7.49 P/C4.96 EPS next 5Y- ROE-39.40% 52W Range17.26 - 40.01 Perf YTD16.67%
Dividend- P/FCF- EPS past 5Y-2.10% ROI-35.20% 52W High-5.42% Beta1.30
Dividend %- Quick Ratio16.20 Sales past 5Y201.60% Gross Margin91.30% 52W Low119.21% ATR1.75
Employees383 Current Ratio16.30 Sales Q/Q20447.20% Oper. Margin- RSI (14)65.37 Volatility4.85% 5.32%
OptionableYes Debt/Eq0.00 EPS Q/Q10.50% Profit Margin- Rel Volume0.35 Prev Close37.10
ShortableYes LT Debt/Eq0.00 EarningsMay 10 BMO Payout- Avg Volume548.60K Price37.83
Recom1.50 SMA2010.97% SMA5012.71% SMA20029.57% Volume123,866 Change1.98%
Dec-15-20Initiated BofA Securities Buy $40
Dec-10-20Initiated Goldman Buy $38
Feb-20-20Initiated Evercore ISI Outperform
Jan-31-20Downgrade JP Morgan Overweight → Neutral $26
Dec-24-19Reiterated Canaccord Genuity Buy $29 → $65
Aug-12-19Initiated Jefferies Buy $16
Feb-26-18Initiated JP Morgan Overweight
Feb-08-18Initiated RBC Capital Mkts Outperform $33
Dec-15-17Initiated Canaccord Genuity Buy $31
Nov-08-17Upgrade SunTrust Hold → Buy
Sep-07-17Upgrade Piper Jaffray Neutral → Overweight
Aug-30-17Upgrade Ladenburg Thalmann Neutral → Buy
Aug-24-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Aug-23-17Upgrade Leerink Partners Mkt Perform → Outperform
May-02-17Downgrade Leerink Partners Outperform → Mkt Perform
May-02-17Downgrade Ladenburg Thalmann Buy → Neutral
May-01-17Downgrade Piper Jaffray Overweight → Neutral
Dec-16-16Initiated Cantor Fitzgerald Overweight
Sep-29-16Reiterated RBC Capital Mkts Outperform $74 → $49
Sep-29-16Downgrade SunTrust Buy → Neutral
May-10-21 03:00PM  
May-05-21 08:00AM  
May-04-21 08:00AM  
May-03-21 07:30AM  
Apr-29-21 05:06PM  
Apr-24-21 08:47AM  
Apr-23-21 03:40AM  
Apr-22-21 07:30AM  
Apr-20-21 07:00AM  
Apr-12-21 07:30AM  
Feb-25-21 08:30PM  
Feb-24-21 10:42AM  
Feb-22-21 08:00AM  
Feb-19-21 08:00AM  
Feb-17-21 08:00AM  
Feb-10-21 02:58AM  
Jan-21-21 08:00AM  
Jan-06-21 08:40AM  
Jan-05-21 08:00AM  
Dec-29-20 08:00AM  
Dec-14-20 01:58PM  
Dec-09-20 08:00AM  
Dec-01-20 05:32AM  
Nov-30-20 08:00AM  
Nov-12-20 06:09AM  
Nov-09-20 06:00PM  
Nov-07-20 07:04AM  
Nov-04-20 08:00AM  
Oct-26-20 08:18AM  
Oct-04-20 06:20AM  
Oct-02-20 07:00AM  
Oct-01-20 04:30PM  
Sep-22-20 11:08AM  
Sep-15-20 08:00AM  
Sep-14-20 08:00AM  
Sep-11-20 08:42AM  
Sep-10-20 08:30PM  
Sep-09-20 05:12PM  
Sep-03-20 08:12AM  
Aug-10-20 05:30PM  
Aug-04-20 11:00AM  
Jul-28-20 10:30AM  
Jul-07-20 08:52AM  
Jun-29-20 08:00AM  
Jun-23-20 09:08PM  
Jun-17-20 04:04PM  
Jun-11-20 09:00AM  
Jun-04-20 08:49AM  
May-26-20 11:05AM  
May-14-20 08:00AM  
May-13-20 04:15PM  
May-09-20 09:52AM  
May-08-20 05:00PM  
May-07-20 11:05AM  
Apr-29-20 08:00AM  
Apr-27-20 09:05AM  
Apr-16-20 04:45PM  
Apr-07-20 06:12PM  
Apr-06-20 11:40PM  
Apr-02-20 08:00AM  
Mar-27-20 10:11AM  
Mar-23-20 07:30AM  
Mar-02-20 07:30AM  
Feb-25-20 08:45AM  
Feb-24-20 08:00AM  
Feb-21-20 04:15PM  
Feb-20-20 05:00PM  
Feb-18-20 10:13AM  
Jan-27-20 12:31PM  
Jan-21-20 08:50AM  
Jan-10-20 09:04AM  
Jan-08-20 08:12AM  
Jan-07-20 09:47PM  
Jan-06-20 04:06PM  
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARCUS JOEL SDirectorMar 02Option Exercise26.5820,000531,60087,519Mar 04 05:43 PM
MARCUS JOEL SDirectorMar 02Sale34.9315,250532,68272,269Mar 04 05:43 PM
Durgam Suresh K.Chief Medical OfficerFeb 19Sale39.252,734107,31023,104Feb 22 08:09 PM
Neumann MarkEVP, Chief Commercial OfficerFeb 19Sale39.225,184203,30845,339Feb 22 08:07 PM
Hineline Lawrence J.SVP of Finance CFOFeb 19Sale39.2310,442409,6250Feb 22 08:05 PM
Halstead MichaelEVP and General CounselFeb 19Sale39.2411,139437,1330Feb 22 08:03 PM
Mates SharonChairman, President & CEOFeb 19Sale39.2327,8471,092,4361,133,392Feb 22 08:01 PM
Durgam Suresh K.Chief Medical OfficerJan 11Sale32.124,367140,25917,484Jan 12 07:07 PM
Neumann MarkEVP, Chief Commercial OfficerJan 11Sale32.029,684310,08239,384Jan 12 07:06 PM
Hineline Lawrence J.SVP of Finance CFOJan 11Sale32.0219,638628,7690Jan 12 07:05 PM
Halstead MichaelEVP and General CounselJan 11Sale32.0319,638628,9780Jan 12 07:03 PM
Mates SharonChairman, President & CEOJan 11Sale32.0141,8961,341,2601,133,392Jan 12 07:01 PM
Hineline Lawrence J.SVP of Finance CFOJan 04Sale31.3115,810495,008350Jan 05 06:13 PM
Halstead MichaelEVP and General CounselJan 04Sale31.3016,160505,8340Jan 05 06:11 PM
Mates SharonChairman, President & CEOJan 04Sale31.3048,3411,513,2711,133,392Jan 05 06:09 PM
Mates SharonChairman, President & CEODec 18Option Exercise2.7434,00093,1601,147,392Dec 21 04:03 PM
Halstead MichaelEVP and General CounselNov 17Option Exercise13.8675,0001,039,50079,425Nov 19 08:05 PM
Halstead MichaelEVP and General CounselNov 17Sale27.6279,4252,193,4460Nov 19 08:05 PM
Hineline Lawrence J.SVP of Finance CFONov 11Option Exercise3.0520,00061,00028,034Nov 13 05:51 PM
Hineline Lawrence J.SVP of Finance CFONov 11Sale25.4128,034712,3440Nov 13 05:51 PM
Mates SharonChairman, President & CEONov 10Sale26.3450,0001,317,1011,113,392Nov 12 05:51 PM
Mates SharonChairman, President & CEONov 04Sale25.0050,0001,250,0001,163,392Nov 06 06:00 PM
Neumann MarkEVP, Chief Commercial OfficerOct 16Sale26.806,792182,02628,120Oct 16 04:04 PM
Alafi Christopher DDirectorSep 14Buy29.6049,5001,465,2004,743,770Sep 14 05:03 PM
Alafi Christopher DDirectorSep 11Buy28.0821,000589,6804,694,270Sep 11 04:15 PM
Hineline Lawrence J.SVP of Finance CFOSep 09Option Exercise12.7326,983343,49450,017Sep 11 07:08 PM
Hineline Lawrence J.SVP of Finance CFOSep 09Sale31.1441,9831,307,3518,034Sep 11 07:08 PM